Neuroendocrine Tumors – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Neuroendocrine Tumors – Pipeline Review, H2 2017’, provides an overview of the Neuroendocrine Tumors pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors

The report reviews pipeline therapeutics for Neuroendocrine Tumors by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Neuroendocrine Tumors therapeutics and enlists all their major and minor projects

The report assesses Neuroendocrine Tumors therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

2X Oncology Inc

AbbVie Inc

Advanced Accelerator Applications SA

Aegis Therapeutics LLC

Amgen Inc

Aquestive Therapeutics

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Celgene Corp

Cielo Therapeutics Inc

Cleave Biosciences Inc

Crinetics Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Dauntless Pharmaceuticals Inc

DexTech Medical AB

Eli Lilly and Co

Esperance Pharmaceuticals Inc

Exelixis Inc

Foresee Pharmaceuticals Co Ltd

Fujifilm Holdings Corporation

Hutchison MediPharma Ltd

Ignyta Inc

Ipsen SA

Jiangsu Hengrui Medicine Co Ltd

Karyopharm Therapeutics Inc

Madrigal Pharmaceuticals Inc.

Mateon Therapeutics Inc

Merck & Co Inc

Merck KGaA

Midatech Pharma Plc

Millennium Pharmaceuticals Inc

Molecular Templates Inc

MolMed SpA

Novartis AG

Peptron Inc

Pfizer Inc

Pharma Mar SA

Progenics Pharmaceuticals Inc

Provectus Biopharmaceuticals Inc

Regulaxis SAS

Strongbridge Biopharma plc

Taiwan Liposome Company Ltd

Tarveda Therapeutics Inc

Valeant Pharmaceuticals International Inc

Vascular Biogenics Ltd

Xencor Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Neuroendocrine Tumors Overview 6

Neuroendocrine Tumors Therapeutics Development 7

Neuroendocrine Tumors Therapeutics Assessment 18

Neuroendocrine Tumors Companies Involved in Therapeutics Development 30

Neuroendocrine Tumors Drug Profiles 52

Neuroendocrine Tumors Dormant Projects 444

Neuroendocrine Tumors Discontinued Products 446

Neuroendocrine Tumors Product Development Milestones 447

Appendix 458

List of Tables

List of Tables

Number of Products under Development for Neuroendocrine Tumors, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Neuroendocrine Tumors Pipeline by 2X Oncology Inc, H2 2017

Neuroendocrine Tumors Pipeline by AbbVie Inc, H2 2017

Neuroendocrine Tumors Pipeline by Advanced Accelerator Applications SA, H2 2017

Neuroendocrine Tumors Pipeline by Aegis Therapeutics LLC, H2 2017

Neuroendocrine Tumors Pipeline by Amgen Inc, H2 2017

Neuroendocrine Tumors Pipeline by Aquestive Therapeutics, H2 2017

Neuroendocrine Tumors Pipeline by AstraZeneca Plc, H2 2017

Neuroendocrine Tumors Pipeline by AVEO Pharmaceuticals Inc, H2 2017

Neuroendocrine Tumors Pipeline by Boehringer Ingelheim GmbH, H2 2017

Neuroendocrine Tumors Pipeline by Celgene Corp, H2 2017

Neuroendocrine Tumors Pipeline by Cielo Therapeutics Inc, H2 2017

Neuroendocrine Tumors Pipeline by Cleave Biosciences Inc, H2 2017

Neuroendocrine Tumors Pipeline by Crinetics Pharmaceuticals Inc, H2 2017

Neuroendocrine Tumors Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Neuroendocrine Tumors Pipeline by Dauntless Pharmaceuticals Inc, H2 2017

Neuroendocrine Tumors Pipeline by DexTech Medical AB, H2 2017

Neuroendocrine Tumors Pipeline by Eli Lilly and Co, H2 2017

Neuroendocrine Tumors Pipeline by Esperance Pharmaceuticals Inc, H2 2017

Neuroendocrine Tumors Pipeline by Exelixis Inc, H2 2017

Neuroendocrine Tumors Pipeline by Foresee Pharmaceuticals Co Ltd, H2 2017

Neuroendocrine Tumors Pipeline by Fujifilm Holdings Corporation, H2 2017

Neuroendocrine Tumors Pipeline by Hutchison MediPharma Ltd, H2 2017

Neuroendocrine Tumors Pipeline by Ignyta Inc, H2 2017

Neuroendocrine Tumors Pipeline by Ipsen SA, H2 2017

Neuroendocrine Tumors Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017

Neuroendocrine Tumors Pipeline by Karyopharm Therapeutics Inc, H2 2017

Neuroendocrine Tumors Pipeline by Madrigal Pharmaceuticals Inc., H2 2017

Neuroendocrine Tumors Pipeline by Mateon Therapeutics Inc, H2 2017

Neuroendocrine Tumors Pipeline by Merck & Co Inc, H2 2017

Neuroendocrine Tumors Pipeline by Merck KGaA, H2 2017

Neuroendocrine Tumors Pipeline by Midatech Pharma Plc, H2 2017

Neuroendocrine Tumors Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Neuroendocrine Tumors Pipeline by Molecular Templates Inc, H2 2017

Neuroendocrine Tumors Pipeline by MolMed SpA, H2 2017

Neuroendocrine Tumors Pipeline by Novartis AG, H2 2017

Neuroendocrine Tumors Pipeline by Peptron Inc, H2 2017

Neuroendocrine Tumors Pipeline by Pfizer Inc, H2 2017

Neuroendocrine Tumors Pipeline by Pharma Mar SA, H2 2017

Neuroendocrine Tumors Pipeline by Progenics Pharmaceuticals Inc, H2 2017

Neuroendocrine Tumors Pipeline by Provectus Biopharmaceuticals Inc, H2 2017

Neuroendocrine Tumors Pipeline by Regulaxis SAS, H2 2017

Neuroendocrine Tumors Pipeline by Strongbridge Biopharma plc, H2 2017

Neuroendocrine Tumors Pipeline by Taiwan Liposome Company Ltd, H2 2017

Neuroendocrine Tumors Pipeline by Tarveda Therapeutics Inc, H2 2017

Neuroendocrine Tumors Pipeline by Valeant Pharmaceuticals International Inc, H2 2017

Neuroendocrine Tumors Pipeline by Vascular Biogenics Ltd, H2 2017

Neuroendocrine Tumors Pipeline by Xencor Inc, H2 2017

Neuroendocrine Tumors Dormant Projects, H2 2017

Neuroendocrine Tumors Dormant Projects, H2 2017 (Contd..1), H2 2017

Neuroendocrine Tumors Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Neuroendocrine Tumors, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports